TRULICITY
A once-weekly GLP-1 receptor agonist containing dulaglutide, made by Eli Lilly of the US. Its approved indication is type 2 diabetes; carried in 0.75 mg and 1.5 mg pens.
- Product type
- Once-weekly GLP-1 receptor agonist
- Ingredients
- Dulaglutide
- Line-up / Units
- TRULICITY 0.75mg / TRULICITY 1.5mg
- Form
- Single-dose pen, 0.75 mg / 1.5 mg (0.5 mL each)
- Manufacturer
- Eli Lilly
- Country of origin
- United States
Key points
- Once-weekly subcutaneous injection
- Approved indication: type 2 diabetes
Contact us for pricing and terms